冠状动脉阻塞性疾病的门诊患者使用他类药物
Suzanne V Arnold1, John A Spertus, Fengming Tang
1MHA, St. Luke's Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111, USA. suz.v.arnold@gmail.com
Circulation
|November 9, 2011
概括
尽管有证据,但许多冠状动脉疾病 (CAD) 患者并没有接受他类药物治疗. 相当一部分未经治疗的CAD患者的LDL胆固醇水平较低,这凸显了脂质管理中的差距.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 临床试验表明,他类药物治疗在降低冠状动脉疾病 (CAD) 患者心血管事件的疗效.
- 这种益处扩展到低密度脂蛋白胆固醇 (LDL-C) 水平低于100mg/dL的患者.
研究的目的:
- 评估在常规门诊护理中,在阻塞性CAD患者中使用他类药物,非他类药物和没有降脂治疗的流行率.
- 为了确定与此种人群中高脂血症治疗不足相关的因素.
主要方法:
- 从ACC的PINNACLE注册表中分析了38775名患有阻塞性CAD的门诊患者.
- 检查了他类药物和非他类降脂药物的处方数据.
- 研究了患者人口统计学,并发症,保险状况和降脂治疗之间的关联.
主要成果:
- 77.8%的患者接受了他类药物治疗,5.3%仅接受了非他类药物治疗,17.0%没有接受治疗.
- 缺乏保险与没有使用他类药物治疗有关;男性性别,高血压和最近的再血管化与他类药物使用有关.
- 在未接受治疗的患者中,53.3%的LDL-C<100 mg/dL.
结论:
- 尽管有强有力的临床证据,但大量阻塞性CAD患者仍未接受他类药物治疗.
- 相当一部分未接受治疗的患者的LDL-C水平低于最佳水平,这表明他们错过了降低心血管风险的机会.
- 对于患有阻塞性CAD的门诊患者,需要改进脂质管理策略.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741